anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
It has been discovered that glucocorticoids prolong nerve blockage produced by release of local anesthetic agents from local delivery systems such as microspheres. The degree of prolongation is proportional to the strength of the glucocorticoid. Preferred anesthetics are local anesthetics that induce local pain relief or numbness, especially bupivacaine, dibucaine, etidocaine, and tetracaine, most preferably the free base of the local anesthetic.  Preferred glucocorticoids are dexamethasone, methylprednisolone, betamethasone, and hydrocortisone. Synthetic polymers are preferred for formation of microparticles for release of the local anesthetic agent and glucocorticoid. The glucocorticoid is preferably incorporated into the polymeric matrix or administered with the microspheres. The microspheres are injected at the site where the anesthetic is to be released. This can be at the time of surgery, or irrigation or perfusion of a wound.
This study is a multi-center, open-label, multiple-dose, safety extension study for patients who have completed another study of STK-001 and meet study eligibility criteria. STK-001 is an investigational new medicine for the treatment of Dravet syndrome. STK-001 is an antisense oligonucleotide (ASO) that is intended to increase the level of productive SCN1A messenger RNA (mRNA) and consequently increase the expression of the sodium channel Nav1.1 protein. This RNA-based approach is not gene therapy, but rather RNA modulation, as it does not manipulate nor insert genetic deoxyribonucleic acid (DNA).

STK-001 is designed to upregulate Nav1.1 protein expression from the nonmutant (wild-type) copy of the SCN1A gene to restore physiological Nav1.1 levels. Nav1.1 levels are reduced in people with Dravet syndrome. Stoke has generated preclinical data demonstrating proof-of-mechanism for STK-001.
A recombinant subunit vaccine of porcine circovirus type 2 (PCV-2) has developed. This recombinant subunit vaccine of pcv-2 is derived from the cloned DNA fragments of the open reading frame 1 (ORF-1) and 2 (ORF-2) from PCV-2 and the porcine interleukin 18 (porcine IL-18) as well. Moreover, the expressed recombinant proteins of ORF-1, ORF-2 and IL-18 described above were made of this recombinant subunit vaccine of PCV-2. Particularly IL-18 was first time used as an adjuvant for this kind of recombinant subunit vaccine of PCV-2 in the world. However, this application for patent is extremely associated with the process for manufacture of this recombinant vaccine of PCV-2. There are three different recombinant expression vectors demonstrate harboring the ORF-1, ORF-2 of PCV-2 and porcine IL-18 gene respectively and also demonstrate the expressed recombinant proteins of ORF-1, ORF-2 of PCV-2 and porcine IL-18 after a procedure of trans formation when E. coli BL-21 (DE-3) or E. coli-star was used as the host cell. Moreover, the expressed recombinant proteins, ORF-1, ORF-2 and IL-18 were not only made of this recombinant subunit vaccine of PCV-2 but also can be scaled up for production indicating a comparative vaccine preparation. However, it revealed that a significant immure protection against porcine circovirus type 2 infections were observed in the pigs after immunization.
Patient-related approaches may show better results in treatment of periodontal diseases. The best way for the dental surgeon to act using these methods is still inconclusive. The aim of this study is to evaluate the effectiveness of using motivational interviewing as part of the treatment of periodontitis in order to increase adult adherence to adequate oral health behavior. A randomized clinical trial, with a sample size of at least 72 subjects, \>18 years of age and with at least 18 teeth, will be investigated. Individuals in the test group will receive a collaborative communicative approach, inspired by the motivational interview, while the control group will receive the information/instructions in a conventional approach. The efficacy variables for evaluating the pattern of self-control of periodontal infection will be the bleeding on probing (BoP), gingival index (GI, primary efficacy variable), the plaque index (PI) and patient-based outcomes will be assessed using quality of life questionnaires. Additionally, questionnaires will be applied to obtain sociodemographic, behavioral and self-perception of oral health data. Univariate and multivariate analyzes will be performed and conducted in the Statistical Products Service Solutions software (SPSS, version 25). Thus, it will be possible to assess whether brief oral health education interventions centered on the individual can be used by dental surgeons in order to effectively improve oral hygiene behaviors in adults, obtaining better clinical results and a better quality of life for patients.
Subjects will be recruited and enrolled to fill one of three Arms. The first Arm will include 25 subjects who are scheduled to receive resurfacing or tightening procedures AS STANDARD OF CARE (CO2 resurfacing or tightening procedure (1 treatment), radiofrequency (2 tx), Fraxel ( 2 tx), or PDL. These subjects will have baseline elasticity measurements recorded on their face and right forearm before their procedures, and follow up measurements will be repeated 3 months following their last treatment. The second Arm will include 25 subjects who are not scheduled to receive any cosmetic procedures but who agree to return for repeated measurements 3 months following the first. Baseline elasticity measurements will be recorded from subjects' face and right forearm and subjects will return in 3 months for follow-up measurements. The third Arm will include the remaining 50 subjects; these subjects will have the elasticity measurements performed only once on their face and forearm.
The etiology of BMS is multifactorial, involving a complex interplay of neuropathic, psychological, neuroendocrine, and immunological factors. Neurologically, BMS has been categorized into three subtypes: peripheral small fiber neuropathy, subclinical trigeminal neuropathy, and inhibitory dopaminergic deficiency. Neuroimaging and peripheral nerve studies have further implicated altered brain activation patterns and increased expression of specific receptors like TRPV1 and P2X3 in the pathogenesis of BMS. Hormonal imbalances, particularly in estrogen levels, have also been suggested to contribute to contribute to the condition.

Caffeine, a xanthine alkaloid chemically known as 1,3,7-trimethylxanthine, is recognized for its diverse biological functions. As a central nervous system stimulant, its primary mechanism involves antagonizing adenosine receptors, thereby enhancing the release of neurotransmitters such as dopamine and norepinephrine, which are known to play roles in analgesic pathways. Caffeine is also noted for its neuroprotective properties and is theorized to reduce the risk of neurodegenerative diseases. It affects the central processing of pain and is involved in regulating circadian rhythms and sleep-wake cycles. Additionally, caffeine has mild anti-inflammatory properties. Its stimulatory effects may also improve mood and cognitive function.
The noFAST group will have post-PEG tube feeds initiated \<1 hour after the procedure. Feeds are to be initiated at the rate and with the formula the patient was tolerating prior to the procedure.
The invention relates to a traditional Chinese medicine composition for treating liver cancer. The traditional Chinese medicine composition in each dose comprises the following components in parts by weight: 10-500 parts of glaucescent fissistigma root extract and 1-100 parts of mono-ammonium glycyrrhizinate. The invention also discloses a method for preparing the traditional Chinese medicine composition. The method comprises the following steps: (1) preparing the glaucescent fissistigma root extract; (2) preparing the mono-ammonium glycyrrhizinate; and (3) preparing the traditional Chinese medicine composition for treating liver cancer, namely adding 10-500 parts of glaucescent fissistigma root extract into 1-100 parts of mono-ammonium glycyrrhizinate, and uniformly mixing to obtain the traditional Chinese medicine composition for treating liver cancer. The traditional Chinese medicine composition has the effects of reducing gastrointestinal tract irritation and improving the cancer treatment effect and is small in toxic and side effects and diversified in action targets, and the medication effectiveness and safety are guaranteed. The application range of various components is widened, and the application limitation is reduced. Moreover, the preparation method has the advantages of simplicity, low cost and environmental friendliness.
SCOPE: This study aims to investigate the effect of sulforaphane (SFN) on hepatic metabolism and gut microbiota in a shifted circadian rhythm (CR) mouse model fed with a high-fat diet (HFD).
METHODS AND RESULTS: A shifted CR mouse model with HFD is constructed. Biochemical analyses are used to evaluate the effects of SFN on lipid accumulation and liver function. Targeted metabolomics is used for liver metabolites. Results from hematoxylin and eosin staining and Oil Red O staining show that SFN improves liver lipid accumulation and intestinal inflammatory damage in shifted CR treatment with HFD. The concentrations of amino acid metabolites are increased, and the levels of bile acid metabolites are significantly decreased by SFN treatment. Results from 16S rRNA gene sequencing indicate that SFN modulates gut microbiota, particularly by enhancing beneficial bacteria such as Lachnospiraceae, Lactobacillus, Alistipes, Akkermansia, and Eubacteriaum coprostanoligenes. Correlation analysis confirms a close relationship between intestinal microbiota and hepatic metabolites. SFN significantly regulates CR protein expression in the hypothalamus and liver tissues.
CONCLUSION: SFN alleviates hepatic metabolic disorder and gut microbiota dysbiosis induced by CR disruption under a high-fat diet in a mouse model, indicating the potential of SFN in regulating CR disruption.
Cases: 30 patients with known paroxysmal atrial fibrillation (pAF) will consecutively be recruited from the cardiology ward and the cardiological ambulatory. They will form the "cases" group.
Rifampin is indicated in the treatment of all forms of tuberculosis.

A three-drug regimen consisting of rifampin, isoniazid, and pyrazinamide [e.g., RIFATER®]5 is recommended in the initial phase of short-course therapy which is usually continued for 2 months. The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and Centers for Disease Control and Prevention recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin, and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.

Following the initial phase, treatment should be continued with rifampin and isoniazid [e.g., RIFAMATE®]6 for at least 4 months. Treatment should be continued for longer if the patient is still sputum or culture positive, if resistant organisms are present, or if the patient is HIV positive.
Health professionals and policymakers rely on evidence synthesized from high quality research studies. Yet, there remain unanswered questions about how to prevent and treat obesity. In this research project, international practice guidelines and Cochrane systematic reviews were examined in order to identify gaps in the synthesized obesity intervention evidence base. One hundred and forty-two partial or complete gaps were found. Systematic review questions to address these gaps were formulated and subjected to a prioritization consultation process with 36 international obesity expert stakeholders. Forty-three review questions were priority-assessed. The top 10 ranked review questions received support from at least 75.0% of stakeholders. The leading questions focused on preventive and community-based approaches, including those delivered through primary-care. Children within the context of their families were a highly-prioritized target group, as were persons with diabetes or disabilities. Experts also prioritized reviews to determine which elements of programs are the most effective, and by which mode they are best delivered. Experts recommended that negative, psycho-social, and longer-term outcomes be captured in reviews. We request reviewers and funders to strongly consider addressing the top 10 leading prioritized review questions presented here.
Nearly two hundred common-variant depression risk loci have been identified by genome-wide association studies (GWAS). However, the impact of rare coding variants on depression remains poorly understood. Here, we present whole-exome sequencing analyses of depression with seven different definitions based on survey, questionnaire, and electronic health records in 320,356 UK Biobank participants. We showed that the burden of rare damaging coding variants in loss-of-function intolerant genes is significantly associated with risk of depression with various definitions. We compared the rare and common genetic architecture across depression definitions by genetic correlation and showed different genetic relationships between definitions across common and rare variants. In addition, we demonstrated that the effects of rare damaging coding variant burden and polygenic risk score on depression risk are additive. The gene set burden analyses revealed overlapping rare genetic variant components with developmental disorder, autism, and schizophrenia. Our study provides insights into the contribution of rare coding variants, separately and in conjunction with common variants, on depression with various definitions and their genetic relationships with neurodevelopmental disorders.
BACKGROUND: Alternative splicing of pre-mRNA is a fundamental regulatory process in multicellular eukaryotes, significantly contributing to the diversification of the human proteome. RNA-binding fox-1 homologue 2 (RBFOX2), a member of the evolutionarily conserved RBFOX family, has emerged as a critical splicing regulator, playing a pivotal role in the alternative splicing of pre-mRNA. This review provides a comprehensive analysis of RBFOX2, elucidating its splicing activity through direct and indirect binding mechanisms. RBFOX2 exerts substantial influence over the alternative splicing of numerous transcripts, thereby shaping essential cellular processes such as differentiation and development.
MAIN BODY OF THE ABSTRACT: Dysregulation of RBFOX2-mediated alternative splicing has been closely linked to a spectrum of cardiovascular diseases and malignant tumours, underscoring its potential as a therapeutic target. Despite significant progress, current research faces notable challenges. The complete structural characterisation of RBFOX2 remains elusive, limiting in-depth exploration beyond its RNA-recognition motif. Furthermore, the scarcity of studies focusing on RBFOX2-targeting drugs poses a hindrance to translating research findings into clinical applications.
CONCLUSION: This review critically assesses the existing body of knowledge on RBFOX2, highlighting research gaps and limitations. By delineating these areas, this analysis not only serves as a foundational reference for future studies but also provides strategic insights for bridging these gaps. Addressing these challenges will be instrumental in unlocking the full therapeutic potential of RBFOX2, paving the way for innovative and effective treatments in various diseases.
The invention relates to a drug for treating tumors and a preparation method thereof. The drug comprises a nanometer drug carrier and a photosensitizer carried by the nanometer drug carrier. A mass ratio of the photosensitizer to the nanometer drug carrier is (0.5-3): 1. The nanometer drug carrier is a graphene quantum dot subjected to PEG modification and heavy atom replacement and has a general formula of PEG-X-GQDs, wherein X represents a heavy atom and GQDs represents a graphene quantum dot. The preparation method comprises 1, adding heavy atom sodium salt and chloramine T into a phosphate buffer solution with the graphene quantum dot, carrying out stirring for a reaction, and then carrying out separation to obtain the heavy atom-substituted graphene quantum dot, 2, adding PEG and EDC/NHS into the aqueous solution of the heavy atom-substituted graphene quantum dot for a reaction, and carrying out separation purification to obtain PEG-X-GQDs, and 3, adding a DMSO solution of the photosensitizer into the PEG-X-GQDs aqueous solution, carrying out stirring for a reaction and carrying out separation to obtain a desired product. Compared with the existing tumor treatment drug, the drug provided by the invention has the advantages of strong targeting, photolytic activity and tumor tissue killing effects.
OBJECTIVES: I. Determine the maximum tolerated dose of intraperitoneal (IP) gemcitabine given in combination with IP cisplatin in patients with refractory or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer. II. Determine the safety of this regimen in this patient population. III. Determine the pharmacokinetics of IP gemcitabine administered with IP cisplatin.

OUTLINE: This is a dose escalation study of gemcitabine. Patients receive intraperitoneal cisplatin on day 1 plus intraperitoneal gemcitabine on days 1, 8, and 15. No treatment will be given on day 22. Courses are repeated every 4 weeks. Patients receive up to 4 courses of therapy. Dose escalation of gemcitabine continues in cohorts of 3 patients until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no more than 2 of 6 patients experience dose limiting toxicity (DLT). Patients are followed every 3 months for 2 years, then every 6 months thereafter.

PROJECTED ACCRUAL: Approximately 3-24 patients will be accrued for this study.
The invention discloses a yeast hollow beta-glucan shell wrapped GMP-BSA protein targeting macrophage delivery system. The system allows BSA to be coated in a yeast shell through using a compact layer formed through the electrostatic adsorption effect of chitosan (CS), tripolyphosphate (TPP), sodium alginate and BSA. GMP-BSA particles prepared in the invention have very good protein release behavior in in-vitro experiments, and can avoid protein loss. The particles highly specifically target the macrophages, such as Raw 264.7 cells, primary BMDM cells (primary bone marrow macrophages) and peritoneal macrophages (PEMs), and are not devoured by NIH3T3, AD293, HeLa, Caco-2 and other non-macrophage tumor cells, and neutral granulocytes in blood. The macrophages play a great role in the pathogenesis of various diseases, and are very important potential target spots. The macrophages are key antigen transfer cells, and are very important in vaccine design. The system can highly selectively deliver various proteins to the macrophages in a targeting manner, and also has very wide application prospect in the field of targeting drug administration and the field of macrophage vaccine design.
Dose Dependent Response: Different doses relative to the participant's body weight will be provided for provision onto the skin before beginning data collection procedures. The 'larger' dose will be composed of 0.8g/kg of the PR Lotion while the 'smaller' dose will be composed of 0.4g/kg of the PR Lotion. Participants will be instructed to apply the lotion primarily to their lower extremities and upper extremities as needed. This lotion will be applied once during the Intervention session of each phase completed and will remain on the skin for approximately 3.5 hours.
The Control Arm of the RCT is the attention control group. These participants will enroll in a web-based psychoeducational group (four groups of 15 parents each). They will receive 6 weeks of online psychoeducational material, including 2-3 push messages prompting skill practice. Parents will have access to an online discussion board to share experiences with other parents. This group will match the intervention arm of the study in number of study staff contacts, time of start/duration of the group, peer support, and availability of a professional in week six for consultation on parenting issues. Control participants will not receive information on media parenting. Participants in this group will be assessed at baseline, immediately following the six-week intervention period, and 3 months after intervention completion. Participants will be asked about exposure to TECH Parenting content at baseline and follow up to address potential contamination effects across study arms.
A therapeutic composition comprises a solution of at least one of the following antibiotic salts: magnesium, calcium or aluminium tetracycline salt or a magnesium, calcium aluminium or zinc oxytetracycline salt in one or more of the following polyhydric aliphatic alcohol solvents: glycerine, polyethylene glycol or propylene glycol, the molar ratio of metal to antibiotic being about 3 : 1 in the case of tetracycline and from 1 : 3 to 3 : 1 in the case of oxytetracycline and the pH of the solution being from 7 to 10. The metal tetracycline or oxtetracycline salts may be prepared in situ and mixed salts of two metals may be employed e.g. calcium, magnesium oxytetracycline or magnesium zinc oxtetracycline.  A non-toxic alkanol, e.g. sorbitol or ethanol may be added in an amount of up to 20% of the solutions.  The compositions are administered (a) intramuscularly or when diluted with water intravenously, (b) as otic or veterinary opthalmic solutions and in humans as otic solutions, mouthwashes or disinfectants, or (c) as salves or suppositories, using as a solvent a high molecular weight polyethylene glycol, e.g. the carbowaxes.  The compositions may contain additionally (a) antibiotics, e.g. streptomycin, polymixin B sulphate, carbomycin or oleandomycin, (b) steroid hormones, e.g. prednisolone, cortisone or hydrocortisone, (c) buffering agents and other stabilizers, e.g. ascorbic acid, triethanolamine, diethanolamine, sodium phosphite, sodium bisulphite and sodium formaldehyde sulphorylate, (d) colouring and flavouring agents, e.g. sodium cyclamate, sodium saccharin, sodium ascorbate, menthol, sodium sucaryl, saccharin, sulphosalicylic acid and benzocain.